Applied BioCode Corporation
TWSE:6598.TW
22 (TWD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 395.169 | 390.302 | 319.962 | 299.015 | 104.694 | 37.145 | 26.756 | 11.76 | 23.249 | 15.187 | 26.619 |
| Cost of Revenue
| 171.638 | 156.132 | 130.595 | 105.491 | 51.725 | 20.413 | 17.842 | 6.865 | 17.008 | 12.461 | 24.6 |
| Gross Profit
| 223.531 | 234.17 | 189.367 | 193.524 | 52.969 | 16.732 | 8.914 | 4.895 | 6.241 | 2.726 | 2.019 |
| Gross Profit Ratio
| 0.566 | 0.6 | 0.592 | 0.647 | 0.506 | 0.45 | 0.333 | 0.416 | 0.268 | 0.179 | 0.076 |
| Reseach & Development Expenses
| 246.005 | 238.37 | 205.854 | 197.005 | 216.973 | 195.709 | 204.544 | 137.877 | 191.01 | 133.148 | 59.611 |
| General & Administrative Expenses
| 117.951 | 109.023 | 91.515 | 85.792 | 73.416 | 62.565 | 51.259 | 52.189 | 25.86 | 25.612 | 20.695 |
| Selling & Marketing Expenses
| 91.196 | 79.381 | 56.941 | 44.241 | 37.653 | 26.337 | 16.959 | 9.394 | 10.741 | 6.757 | 5.071 |
| SG&A
| 164.228 | 188.404 | 148.456 | 130.033 | 111.069 | 88.902 | 68.218 | 61.583 | 36.601 | 32.369 | 25.766 |
| Other Expenses
| 1.466 | 2.167 | -0.474 | 30.623 | 1.613 | 0.251 | 0.412 | 2.533 | 198.706 | 86.697 | -125.907 |
| Operating Expenses
| 410.233 | 426.774 | 354.31 | 327.038 | 328.042 | 284.611 | 272.762 | 199.46 | 227.611 | 165.517 | 85.377 |
| Operating Income
| -186.702 | -181.926 | -162.306 | -99.159 | -273.46 | -267.628 | -263.848 | -194.565 | -221.37 | -162.791 | -83.358 |
| Operating Income Ratio
| -0.472 | -0.466 | -0.507 | -0.332 | -2.612 | -7.205 | -9.861 | -16.545 | -9.522 | -10.719 | -3.132 |
| Total Other Income Expenses Net
| 23.261 | -2.784 | -2.87 | -4.313 | -6.589 | -0.653 | 0.412 | 2.533 | 198.706 | 86.697 | -125.907 |
| Income Before Tax
| -163.441 | -184.71 | -165.176 | -103.472 | -280.049 | -268.281 | -263.436 | -192.032 | -22.664 | -76.094 | -209.265 |
| Income Before Tax Ratio
| -0.414 | -0.473 | -0.516 | -0.346 | -2.675 | -7.223 | -9.846 | -16.329 | -0.975 | -5.01 | -7.861 |
| Income Tax Expense
| 0.758 | 0.023 | 0.023 | 0.024 | 0.024 | 0.024 | 0.024 | -8.799 | -1.402 | -4.922 | -1.245 |
| Net Income
| -164.199 | -184.733 | -165.199 | -103.496 | -280.073 | -268.305 | -263.46 | -135.876 | -21.262 | -71.172 | -208.02 |
| Net Income Ratio
| -0.416 | -0.473 | -0.516 | -0.346 | -2.675 | -7.223 | -9.847 | -11.554 | -0.915 | -4.686 | -7.815 |
| EPS
| -2.01 | -2.26 | -2.02 | -1.33 | -4.36 | -5.06 | -5.66 | -3.15 | -0.73 | -2.98 | -9.63 |
| EPS Diluted
| -2.01 | -2.26 | -2.02 | -1.33 | -4.36 | -5.06 | -5.65 | -3.11 | -0.73 | -2.98 | -9.63 |
| EBITDA
| -124.018 | -125.414 | -111.347 | -55.564 | -240.652 | -250.995 | -250.788 | -183.146 | -211.762 | -155.678 | -78.141 |
| EBITDA Ratio
| -0.314 | -0.321 | -0.348 | -0.186 | -2.299 | -6.757 | -9.373 | -15.574 | -9.108 | -10.251 | -2.936 |